Drug Trial Radar · NCT06270706
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Aug 30, 2023
Primary completion
Jun 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- Pliant Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from the start of treatment with pembrolizumab. The study will consist of 2 main parts: * Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with accelerated titration * Part 2: Dose-expansion cohorts using Simon's 2-stage design
Conditions
- Advanced or Metastatic Solid Tumor
Interventions
PLN-101095Drug
PLN-101095 250 mg BID
PLN-101095Drug
PLN-101095 500 mg BID
PLN-101095Drug
PLN-101095 1000 mg BID
PLN-101095Drug
PLN-101095 1000 mg TID
PLN-101095Drug
PLN-101095 2000 mg BID
PLN-101095Drug
PLN-101095
PembrolizumabDrug
Pembrolizumab (KEYTRUDA) 200 mg IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2Time frame: First dose to 35 days
- Safety and tolerability of PLN-101095 in combination with pembrolizumab in Parts 1 and 2Time frame: Day 1 until 16 weeks after end of study treatment regimen
- Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2Time frame: First dose to disease progression or death from any cause, whichever occurs first.
- Anti-tumor activity of PLN-101095 in combination with pembrolizumab in Part 2Time frame: First dose to disease progression or death from any cause, whichever occurs first.
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
Yale University
New Haven, Connecticut · Completed
Georgetown University Medical Center
Washington D.C., District of Columbia · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
South Texas Accelerated Research Therapeutics (START)
Grand Rapids, Michigan · Recruiting
Washington University Medicine
St Louis, Missouri · Recruiting
START New Jersey
East Brunswick, New Jersey · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
START New York Long Island LLC
Lake Success, New York · Recruiting
Carolina Cancer Research Center
Wilson, North Carolina · Recruiting
Avera Medical Group
Sioux Falls, South Dakota · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
NEXT Austin
Austin, Texas · Recruiting
START Center for Clinical Research
Fort Worth, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Houston
Houston, Texas · Recruiting
UT Health San Antonio's Mays Cancer Center
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
Inova Schar Cancer Institute
Fairfax, Virginia · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Swedish Cancer Institute Medical Oncology
Edmonds, Washington · Recruiting
Hospital Universitari Quirónsalud (NEXT Barcelona)
Barcelona, Barcelona, Spain · Recruiting
START Barcelona - Hospital HM Nou Delfos
Barcelona, Barcelona, Spain · Recruiting
Hospital Universitari Vall d'Hebron - VHIO
Barcelona, Barcelona, Spain · Recruiting
START Center for Cancer Research - La Rioja
Logroño, La Rioja, Spain · Recruiting
START Madrid - Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, Spain · Recruiting
START Madrid - Centro Integral Oncológico Clara Campal
Madrid, Madrid, Spain · Recruiting
University Hospital Quironsalud Madrid (NEXT Madrid)
Madrid, Pozuelo de Alarcón, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.